RxSight, Inc. (RXST)

Market Cap	316.56M
Revenue (ttm)	147.06M
Net Income (ttm)	-32.25M
Shares Out	40.64M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,198,108
Open	7.67
Previous Close	7.55
Day's Range	7.26 - 7.79
52-Week Range	6.32 - 58.23
Beta	1.15
Analysts	Hold
Price Target	13.80 (+77.15%)
Earnings Date	Aug 7, 2025

About ACCD

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: RXST
• Website: https://www.rxsight.com

Financial Performance

In 2024, RxSight's revenue was $139.93 million, an increase of 57.09% compared to the previous year's $89.08 million. Losses were -$27.46 million, -43.52% less than in 2023.

Analyst Summary

According to 11 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $13.8, which is an increase of 77.15% from the latest price.

Price Target

$13.8

(77.15% upside)

Analyst Consensus: Hold